BMS at ESC congress 2023
We’re excited to share updates across our innovative cardiovascular portfolio at this year’s European Society of Cardiology (ESC) Congress. We will highlight key research programs that reaffirm our steadfast dedication to tackling cardiovascular disease for patients across the globe.
Our data at ESC 2023
At ESC Congress 2023, Bristol Myers Squibb is presenting data from our cardiovascular portfolio, including follow-up results from two Phase 3 long-term extension studies of our treatment for patients with symptomatic obstructive hypertrophic cardiomyopathy (HCM) as a late-breaking and oral presentation, and an observational retrospective real-world data study to assess the clinical impact of switching or continuation of direct oral anticoagulants among patients with non-valvular atrial fibrillation (NVAF) for stroke risk reduction, sponsored by the Bristol Myers Squibb-Pfizer Alliance.
These data reinforce our goal of bringing innovative and life-changing medicines to patients living with cardiovascular diseases.
As a leader in cardiovascular research, we have pioneered the science behind many game-changing targets, and over the years, we have made a meaningful difference in the lives of millions of people around the world. However, despite these many advances from Bristol Myers Squibb and the field in general, cardiovascular disease continues to be the leading cause of death globally.
We are determined to fundamentally change how we approach prevention and treatment of cardiovascular disease in the future and focusing our efforts on finding new approaches to treat cardiovascular diseases.
HCM is the most commonly inherited cardiovascular disease. Learn more about its prevalence and symptoms from Roland Chen, senior vice president and head of Cardiovascular & Neuroscience Development, Global Drug Development at BMS.
Our research in cardiovascular follows a science-driven pathway approach that delivers scientific innovation across key areas of focus.